胶质母细胞瘤放疗结合替莫唑胺治疗对比单独放疗的Meta分析

发布时间：2018-04-13 06:20

本文选题：放射疗法 + 药物疗法　；参考：《重庆医学》2017年25期

【摘要】：目的评价胶质母细胞瘤患者放疗结合替莫唑胺治疗方案的有效性和安全性。方法按Cochrane系统评价方法,分别检索Pubmed、Cochrane library、Medline、OVID数据库,对纳入的文献进行质量评估,提取数据后进行Meta分析。结果纳入的研究中替莫唑胺组对比单独放疗组汇总显示:12个月总生存率[RR1.22,95%CI(1.01,1.47),P=0.04]、24个月总生存率[RR2.65,95%CI(1.86,3.78),P0.01],差异均有统计学意义。12个月无进展生存率[RR2.59,95%CI(1.53~4.40),P=0.000 4]、24个月无进展生存率[RR6.77,95%CI(2.82~16.26),P0.01],差异也有统计学意义。血液毒性反应:替莫唑胺组中同步治疗期对比放疗期[RR3.21,95%CI(1.89,5.46),P0.01];替莫唑胺组中辅助治疗期对比放疗组[RR6.11,95%CI(3.70,10.09),P0.01];替莫唑胺组中同步治疗期对比辅助治疗期[RR0.48,95%CI(0.36,0.65),P0.01],差异均有统计学意义;非血液毒性反应事件[RR1.11,95%CI(0.72,1.70),P=0.64],差异无统计学意义。结论放疗结合同步和随后辅助替莫唑胺治疗提高了胶质母细胞瘤患者的总生存期和无进展生存期,较高血液毒性反应发生率与替莫唑胺治疗药物相关。
[Abstract]:Objective to evaluate the efficacy and safety of radiotherapy combined with temozolamide in patients with glioblastoma.Methods according to the method of Cochrane system evaluation, the database of Pubmeda Cochrane libraryary Medline Ovid was searched, and the quality of the literature was evaluated. The data were extracted and analyzed by Meta.There is also statistical significance.There was no significant difference in non-hematological reaction events (RR1.1195) between two groups (RR1.1195, CI0.22, 1.70, P0. 64, RR1.1195, RR1.1195, RR1.1195).Conclusion radiotherapy combined with concurrent and subsequent treatment with temozolidomide can improve the overall survival and progression free survival of glioblastoma patients. The high incidence of blood toxicity is associated with the treatment of temozolidomide.
【作者单位】：华北理工大学附属医院神经外科;河北省肃宁县人民医院神经外科;华北理工大学附属医院护理部;
【分类号】：R739.41

【相似文献】